Vland Biotech(SH:603739)2023-10-27 16:00Financial Performance - The company's revenue for Q3 2023 reached ¥335,697,770.62, representing a year-on-year increase of 13.10%[5] - Net profit attributable to shareholders for Q3 2023 was ¥23,853,431.86, up 41.93% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥17,678,485.62, an increase of 30.48% year-on-year[5] - The basic earnings per share for Q3 2023 was ¥0.09, reflecting a 28.57% increase compared to the same period last year[6] - The company reported a net profit of ¥59.45 million for the first three quarters of 2023, compared to ¥53.15 million in the same period of 2022, representing an increase of 11.00%[19] - The total comprehensive income for Q3 2023 was CNY 67,282,409.12, compared to CNY 62,858,384.16 in Q3 2022, marking an increase of approximately 7.2%[20] Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥45,221,572.21, reflecting a 31.58% increase compared to the previous year[5] - The net cash flow from operating activities for the first nine months of 2023 was CNY 45,221,572.21, up from CNY 34,367,649.09 in the previous year, indicating a year-over-year increase of approximately 31.5%[23] - The company reported a net cash outflow from investing activities of CNY -207,692,510.84 for the first nine months of 2023, an improvement from CNY -285,789,311.80 in the same period of 2022[23] - The net cash flow from financing activities for Q3 2023 was CNY 183,139,915.86, compared to CNY 235,531,923.59 in Q3 2022, showing a decrease of about 22.3%[24] Assets and Liabilities - The total assets as of the end of Q3 2023 amounted to ¥2,926,073,403.72, a 13.46% increase from the end of the previous year[6] - The company's total assets as of September 30, 2023, amounted to ¥2.93 billion, up from ¥2.58 billion at the end of 2022, representing a growth of 13.49%[16] - Current assets totaled ¥1.14 billion as of September 30, 2023, compared to ¥969.40 million at the end of 2022, indicating an increase of 17.19%[15] - The company's total liabilities reached ¥1.11 billion as of September 30, 2023, compared to ¥844.93 million at the end of 2022, reflecting a rise of 31.56%[16] - The equity attributable to shareholders increased to ¥1.69 billion as of September 30, 2023, from ¥1.64 billion at the end of 2022, showing a growth of 2.93%[17] - Cash and cash equivalents stood at ¥228.36 million as of September 30, 2023, compared to ¥213.87 million at the end of 2022, an increase of 6.93%[14] Revenue Growth - The enzyme preparation business revenue increased by ¥22,281,900, representing a year-on-year growth of 21.39%[9] - Total revenue for the first three quarters of 2023 reached ¥879.64 million, an increase of 6.05% compared to ¥829.41 million in the same period of 2022[19] - Total operating costs for the first three quarters of 2023 were ¥820.19 million, up from ¥775.65 million in 2022, reflecting a year-on-year increase of 5.73%[19] - Research and development expenses increased to ¥81.20 million in the first three quarters of 2023, compared to ¥72.26 million in 2022, marking an increase of 12.66%[19] - The total revenue from operating activities for the first nine months of 2023 was CNY 926,565,339.38, compared to CNY 829,321,694.69 in the same period of 2022, reflecting a growth of about 11.7%[23] Strategic Focus - The company has focused on R&D investments to develop high-efficiency enzyme products, improving both performance and cost[9] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[19]